<DOC>
	<DOCNO>NCT01417065</DOCNO>
	<brief_summary>The goal clinical research trial study effect FDA-approved drug , temsirolimus , use new type clinical study design call `` Phase 0 . '' This type study may able predict drug affect cancer may able prevent potentially useful study drug discard fully test . The purpose study treat cancer , help improve general cancer treatment knowledge .</brief_summary>
	<brief_title>Temsirolimus In Phase 0</brief_title>
	<detailed_description>Study Drug : Temsirolimus design block growth cancer cell , may cause cancer cell die . Study Drug Administration : If find eligible take part study , receive temsirolimus vein 60 minute Day 1 . You assign dose level temsirolimus base join study . Up 5 dose level temsirolimus test . Up 3 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , drug find affect enzyme test screening . Study Visits : At study visit , ask drug may take side effect may . On Day 1 : -Blood ( 2 teaspoon time ) drawn receive study drug 5 time 24 hour receive study drug pharmacokinetic ( PK ) test . PK test measure amount study drug body different time point . Blood ( 4 teaspoon time ) drawn pharmacodynamic ( PD ) test . PD test measure level study drug body may affect disease . This blood draw 1 follow time , doctor think need , blood drawn 2 3 follow time : - At 4 hour ( +/- 2 hour ) dose - At 24 hour ( +/- 3 hour ) dose - At 72 hour ( +/- 24 hour ) dose After blood PD test tested test show study drug may cause change tumor cell least 2 3 participant , future participant tumor tissue collect dose test . Leftover tissue earlier biopsy use instead fresh biopsy dosing , available . Length Study : You study 4 day . You take study early intolerable side effect . Because take 4 day temsirolimus completely process body , able begin receive drug study 4 day dose . This investigational study . Temsirolimus FDA approve commercially available treatment advance renal cancer . Its use type cancer investigational . Up 30 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patients advance metastatic cancer , preferably tumor easily accessible biopsy . 2 . Patients least four week 5 half life last day chemotherapy , antibody biological therapy , whichever short . 3 . Patients preferably undergo screen 20070668 , 20080384 , 20080425 , 20080827 ( currently active Phase I trials involve temsirolimus ) . However , patient may also allow protocol undergo screen study . 1 . Pregnant lactating woman . 2 . Patients know hypersensitivity component metabolites drug product . 3 . Patients know bleeding diathesis would prevent safely obtain biopsy biopsy indicate . 4 . Patients le 18 year age .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>mTOR inhibitor Temsirolimus</keyword>
	<keyword>Torisel</keyword>
	<keyword>CCI-779</keyword>
	<keyword>pharmacodynamic target</keyword>
</DOC>